Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-Up Study of Tofacitinib in JIA
NCT01500551Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2013
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib oral solution in juvenile idiopathic arthritis (JIA), sponsored by Pfizer. Primary endpoints: Number of Participants With Laboratory Test Abnormalities up to 118 months, Number of Participants With Treatment-Emergent Adverse Events up to 118 months and 3 more. Started Mar 2013; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT01500551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500551.